L’anticorps anti-s100a4 Monoclonal produit chez le Souris a été validé pour FACS, EIA, ELISA (Capture) et ELISA (Detection). Il convient pour la détection de s100a4 dans des échantillons provenant de Humain.
}
Recognizes Human S100 Calcium Binding Protein A4 (S100A4). Other species not tested.
Purification
Affinity Chromatography on Protein G
Immunogène
Genetic immunisation with cDNA encoding S100A4. Selection: based on recognition of the complete native protein expressed on transfected mammalian cells.
Flow cytometry: 1.2 μg/10 6 cells. ELISA: 1/200-1/400. ELISA (capture): Clone NJ-4F3-D1 as detection antibody. ELISA (detection): Clone NJ-5C6-A3 as capture antibody. Cell based ELISA with intakt, transiently transfected cells: 1/200-1/400.
Restrictions
For Research Use only
Format
Liquid
Buffer
Phosphate buffered saline, pH 7.2
Stock
4 °C,-20 °C
Stockage commentaire
Store undiluted at 2-8°C for one month or (in aliquots) at -20°C for longer. Avoid repeated freezing and thawing. Shelf life: one year from despatch.
Date de péremption
12 months
Antigène
s100a4 (S100A4)
(S100 Calcium Binding Protein A4 (S100A4))
Autre désignation
s100a4
Sujet
S100 calcium binding protein A4 (S100A4) is a member of the S100 family of calcium-binding proteins that contain two Ca(2+)-binding sites including a canonical EF-hand motif. S100 proteins are localized in the cytoplasm and/or nucleus of a wide range of cells. S100A4 interacts with cytoskeletal proteins and enhances metastasis of several types of cancer cells. It is secreted by unknown mechanisms, thus, paracrinely stimulating a variety of cellular responses, including angiogenesis and neuronal growth (1). S100A4 has been shown to be a prognostic marker in a number of human cancers, including esophageal-squamous cancers, non-small lung cancers, primary gastric cancers, malignant melanomas, prostate cancers, bladder cancers, and pancreatic carcinomas. The universality of S100A4 expression in a variety of cancers illustrates the potential use of S100A4 as a marker for tumor metastasis and disease progression (2).